SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Are the Economics of Pharmaceutical Research and Development Changing?
6 references·2 citing·35 second hop
Are the Economics of Pharmaceutical Research and Development Changing? (2004)Are the Economics of Pharmaceutical Resea…Innovation Policy and the Economy (2007)Innovation Policy and the Eco…The price of innovation: new estimates of drug development costs (2003)The price of innovation: new …Returns on Research and Development for 1990s New Drug Introductions (2002)Returns on Research and Devel…The Link Between Gross Profitability And Pharmaceutical R&D Spending (2001)The Link Between Gross Profit…Longer Patents for Increased Generic Competition in the US (1996)Longer Patents for Increased …Research and Development Costs and Returns: The U.S. Pharmaceutical Industry (1972)Research and Development Cost…Physical scientists research biomedicine: a call for caution. (2015)Physical scientists research …The Market For Follow-On Biologics: How Will It Evolve? (2006)The Market For Follow-On Biol…The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries (1968)Demand-Pull and Technological Invention: Schmookler Revisted (1982)R & D and Internal Finance: A Panel Study of Small Firms in High-Tech Industries (1994)Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price (2002)Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? (2008)Economics of the Pharmaceutical Industry (2018)Is Aggregation Necessarily Bad? (1960)Economic Welfare and the Allocation of Resources for Invention (1962)Invention, Growth and Welfare. (1970)THE VERTICAL CHAIN OF RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY (1995)The Stock Market Valuation of Research and Development Expenditures (1999)Is the Pharmaceutical Industry in a Productivity Crisis? (2006)Cost of innovation in the pharmaceutical industry (1991)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Price Competition in Pharmaceuticals: The Case of Anti‐infectives (2004)Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States (2016)Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry (2016)Generic Competition in the US Pharmaceutical Industry (2006)The cost of biopharmaceutical R&D: is biotech different? (2007)IP Issues of Therapeutic Antibodies (2012)The biotechnology sector and US gene patents: Legal challenges to intellectual property rights and the impact on basic research and development (2012)Determinants of Market Exclusivity for Prescription Drugs in the United States (2017)Is Technological Change In Medicine Worth It? (2001)The Value of Improving the Productivity of the Drug Development Process (2002)Firm growth and R&D expenditure (2009)US biopharmaceutical finance and the sustainability of the biotech business model (2011)Does international research and development increase patent output? An analysis of Japanese pharmaceutical firms (2004)Measuring the change in R&D efficiency of the Japanese pharmaceutical industry (2008)The top 100 papers (2014)Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry (2004)In the Shadow of a Giant: Medicare’s Influence on Private Physician Payments (2016)Overlapping Ownership, R&D Spillovers, and Antitrust Policy (2018)Can the pharmaceutical industry reduce attrition rates? (2004)Clinical development success rates for investigational drugs (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)
this work references cited by second hop

References

  • 2003The price of innovation: new estimates of drug development costs4,264 cited
  • 2007Innovation Policy and the Economy462 cited
  • 2002Returns on Research and Development for 1990s New Drug Introductions311 cited
  • 2001The Link Between Gross Profitability And Pharmaceutical R&D Spending183 cited
  • 1996Longer Patents for Increased Generic Competition in the US136 cited
  • 1972Research and Development Costs and Returns: The U.S. Pharmaceutical Industry96 cited

Cited by

  • 2006The Market For Follow-On Biologics: How Will It Evolve?79 cited
  • 2015Physical scientists research biomedicine: a call for caution.9 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work